Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zimmer’s Female-Specific Knee Beats High Expectations In Fourth Quarter

This article was originally published in The Gray Sheet

Executive Summary

Implants of over 9,500 Zimmer Gender Solutions knee replacement systems in the fourth quarter of 2006 helped drive the firm's worldwide knee revenue ahead 11%, year-over-year, to $389 million

You may also be interested in...



Hip Resurfacing Technology Aids S&N Stock Gain In Q1 - Index Up 1.1%

Investor enthusiasm for hip resurfacing's market potential was among factors contributing to Smith & Nephew's 21.3% stock price gain in the first quarter

Hip Resurfacing Technology Aids S&N Stock Gain In Q1 - Index Up 1.1%

Investor enthusiasm for hip resurfacing's market potential was among factors contributing to Smith & Nephew's 21.3% stock price gain in the first quarter

Wright steps up to competition with “stature-specific” knee

Wright Medical launches its Advance Stature femoral component knee system March 15. Similar to Zimmer's Gender Solutions knee replacement system, Advance Stature is designed for smaller patients. Wright maintains, however, that "patient size (stature or height), not gender, is a more appropriate determinant of implant needs." Compared with conventional knee implants, Wright's system features "a reduced width and contoured anterior flange for optimized patellar tracking," according to the firm. Zimmer has reported stronger than anticipated demand for Gender Solutions since its debut last May (1"The Gray Sheet" Feb. 5, 2007, p. 7)...

Related Content

UsernamePublicRestriction

Register

OM017175

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel